<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156076</url>
  </required_header>
  <id_info>
    <org_study_id>CV205-005</org_study_id>
    <nct_id>NCT02156076</nct_id>
  </id_info>
  <brief_title>A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF)
      through its effect on AF burden (AFB), or the percent of time in AF, in subjects with
      paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg
      QD, 12 mg QD following a 1-week period of loading doses of 3 mg QD, 8 mg QD and 20 mg QD,
      respectively) for a total of 4 weeks. It is hypothesized that treatment with BMS-919373 will
      reduce AF burden as compared to baseline relative to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: Protocol designed to assess, by the use of long term non-invasive
      beat-to-beat monitoring with the SEEQ Mobile Cardiac Telemetry (MCT) system, the effect of
      BMS-919373 on the percent change from baseline relative to placebo of atrial fibrillation
      burden in subjects with paroxysmal atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in Atrial Fibrillation Burden (percent of time in which a subject is in Atrial Fibrillation)</measure>
    <time_frame>Day 8 to Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will be based on review of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests collected at specified time points and continuous monitoring of safety events of special interest</measure>
    <time_frame>From initiation of study drug until follow up visit (approximately 50 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of BMS-919373</measure>
    <time_frame>Day 1 and Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed concentration (Cmin) of BMS-919373</measure>
    <time_frame>Day 8, Day 22, and Day 29</time_frame>
    <description>Estimates of individual exposure parameters will be derived from the population pharmacokinetics (PK) model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F) of BMS-919373</measure>
    <time_frame>Day 36, Day 50</time_frame>
    <description>PK data collected will be used to develop a population PK model to estimate model-based parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central volume of distribution (Vc/F) of BMS-919373</measure>
    <time_frame>Day 8, Day 22, and Day 29</time_frame>
    <description>PK data collected will be used to develop a population PK model to estimate model-based parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absorption rate constant (Ka) of BMS-919373</measure>
    <time_frame>Day 8, Day 22, and Day 29</time_frame>
    <description>PK data collected will be used to develop a population PK model to estimate model-based parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration (Cavg) of BMS-919373</measure>
    <time_frame>Day 8, Day 22, and Day 29</time_frame>
    <description>Estimates of individual exposure parameters will be derived from the population PK model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) at steady state of BMS-919373</measure>
    <time_frame>Day 8, Day 22, and Day 29</time_frame>
    <description>Estimates of individual exposure parameters will be derived from the population PK model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on time to first AF recurrence (symptomatic or asymptomatic)</measure>
    <time_frame>From initiation of study drug until follow up visit (approximately 50 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on number of AF episodes</measure>
    <time_frame>From initiation of study drug until follow up visit (approximately 50 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on average duration of AF per episode</measure>
    <time_frame>From initiation of study drug until follow up visit (approximately 50 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Arm A: Placebo (Matching with BMS-919373)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-919373 3 mg tablets orally once daily for approximately 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-919373 5 mg tablets orally once daily for approximately 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-919373 12 mg tablets orally once daily for approximately 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-919373</intervention_name>
    <arm_group_label>Arm B: BMS-919373</arm_group_label>
    <arm_group_label>Arm C: BMS-919373</arm_group_label>
    <arm_group_label>Arm D: BMS-919373</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Matching with BMS-919373)</intervention_name>
    <arm_group_label>Arm A: Placebo (Matching with BMS-919373)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Signed informed consent

          -  Paroxysmal Atrial Fibrillation (pAF) with available documentation of AF and reporting
             symptoms within 6 months prior to screening

          -  Able to tolerate withdrawal of antiarrhythmic therapy (rhythm control)

          -  Echocardiographically measured left ventricular ejection fraction (LVEF) ≥40%,measured
             within 12 months of enrollment

          -  Echocardiographically measured left atrial (LA) diameter ≤ 5.0 cm, measured within 12
             months of enrollment

        Exclusion Criteria:

          -  Women of childbearing potential

          -  AFB &lt; 3% or &gt; 70%, during both screening periods independently

          -  Permanent or persistent Atrial Fibrillation

          -  Cardioversion within 3 months of study drug administration

          -  Stroke within 12 months of study drug administration

          -  TIA within 12 months of study drug administration

          -  Heart failure of NYHA class III or greater (symptoms of heart failure at rest or with
             minimal exertion)

          -  Heart failure of NYHA class II (symptoms of heart failure with routine levels of
             exertion)with ejection fraction &lt;40% as measured by echocardiography at any time
             within 12 months of study enrollment (i.e. additional ejection fraction measurements ≥
             40% over this period will not counter this exclusion)

          -  Valvular heart disease (including any valvular insufficiency or stenosis greater
             than&quot;mild&quot;)

          -  Ablation within 3 months of study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Consultants Of Orange County Med. Group Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oracle Clinical Research, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wcct Global, Llc</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Va Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Clinical Research</name>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, Llc</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Medical Research, Llc</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiac And Vascular Institute Research Foundation, Llc</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acrc Cardiology</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Institute At Largo</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Heart And Vascular Specialists, Llc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Medical Trials</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castlerock Clinical Research Consultants, Llc</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Area Research, Llc</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Center For Clinical Trials</name>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <zip>37388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cardiology P.C</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Clinical Trials Inc.</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Andy S.C. Lam Medicine Professional</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <zip>L3M 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroke Prevention &amp; Artherosclerosis Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Street Cardiology</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2T 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viacar Recherche Clinique</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csss Du Sud De Lanaudiere-Hopital Pierre-Le Gardeur</name>
      <address>
        <city>Terrebonne</city>
        <state>Quebec</state>
        <zip>J6V 2H2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <disposition_first_submitted>March 22, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 24, 2017</disposition_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

